804 related articles for article (PubMed ID: 22920906)
1. The therapeutic target Hsp90 and cancer hallmarks.
Miyata Y; Nakamoto H; Neckers L
Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
3. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
4. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
5. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
[TBL] [Abstract][Full Text] [Related]
6. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
7. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
8. The Right Tool for the Job: An Overview of Hsp90 Inhibitors.
Koren J; Blagg BSJ
Adv Exp Med Biol; 2020; 1243():135-146. PubMed ID: 32297216
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
12. Targeting HSP90 for cancer therapy.
Mahalingam D; Swords R; Carew JS; Nawrocki ST; Bhalla K; Giles FJ
Br J Cancer; 2009 May; 100(10):1523-9. PubMed ID: 19401686
[TBL] [Abstract][Full Text] [Related]
13. HSP90 and its inhibitors.
Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Takaoka M
Oncol Rep; 2010 Jun; 23(6):1483-92. PubMed ID: 20428801
[TBL] [Abstract][Full Text] [Related]
14. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
Tsutsumi S; Neckers L
Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
[TBL] [Abstract][Full Text] [Related]
15. Human Hsp90 cochaperones: perspectives on tissue-specific expression and identification of cochaperones with similar in vivo functions.
Dean ME; Johnson JL
Cell Stress Chaperones; 2021 Jan; 26(1):3-13. PubMed ID: 33037995
[TBL] [Abstract][Full Text] [Related]
16. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
17. Maximizing the Therapeutic Potential of HSP90 Inhibitors.
Butler LM; Ferraldeschi R; Armstrong HK; Centenera MM; Workman P
Mol Cancer Res; 2015 Nov; 13(11):1445-51. PubMed ID: 26219697
[TBL] [Abstract][Full Text] [Related]
18. A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor α methylation by the lysine methyltransferase SMYD2.
Obermann WMJ
J Biol Chem; 2018 Oct; 293(42):16479-16487. PubMed ID: 30190324
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the interaction of Aha1 with components of the Hsp90 chaperone machine and client proteins.
Sun L; Prince T; Manjarrez JR; Scroggins BT; Matts RL
Biochim Biophys Acta; 2012 Jun; 1823(6):1092-101. PubMed ID: 22504172
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in Hsp90 inhibitors as antitumor agents.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Anticancer Agents Med Chem; 2008 Oct; 8(7):761-82. PubMed ID: 18855578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]